Recorlev® is a potent inhibitor of key adrenal steroidogenesis enzymes
Recorlev inhibits 3 key enzymes involved in the synthesis of cortisol and testosterone at lower concentrations than its racemic counterpart, as seen in preclinical studies1-4
MOA=mechanism of action.
References: 1. Recorlev [prescribing information]. Chicago, IL; Xeris Pharmaceuticals, Inc. 2. Creemers SG, Feelders RA, de Jong FH, et al. Levoketoconazole, the 2S,4R enantiomer of ketoconazole, a new steroidogenesis inhibitor for Cushing’s syndrome treatment. J Clin Endocrinol Metab. 2021;106(4):e1618-e1630. doi:10.1210/clinem/dgaa989. 3. Fleseriu M, Auchus RJ, Pivonello R, Salvatori R, Zacharieva S, Biller BMK. Levoketoconazole: a novel treatment for endogenous Cushing’s syndrome. Expert Rev Endocrinol Metab.2021;16(4):159-174. 4. Auchus RJ, Wu Y, Liu J, Peng HM. 2S,4R-ketoconazole is the relevant enantiomer of ketoconazole for cortisol synthesis inhibition: steroidogenic P450s inhibition involves multiple mechanisms. Poster presented at: the Endocrine Society 100th Annual Meeting; March 17-20, 2018; Chicago, IL.